Acrivon Therapeutics is a series c plus startup. 1 investor tracked. Status: possibledead.
Acrivon Therapeutics is a company headquartered in the United States. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
Acrivon Therapeutics is a biopharmaceutical company leveraging its proprietary proteomics-based patient responder ID platform, Acrivon Predictive Precision (APPTM), to develop highly-selective oncology drugs.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.